The novel agent prexasertib showed promising activity and was reasonably well tolerated in a phase II study of high-grade, heavily pretreated, BRCA wild-type serous ovarian carcinoma.
Treatment with hyperthermic intraperitoneal chemotherapy along with cytoreductive surgery resulted in better survival outcomes than surgery alone in patients with stage III epithelial ovarian cancer, according to a new study.
Adding abiraterone plus prednisone to ADT improves patient-reported outcomes and quality of life in patients with metastatic castration-naive prostate cancer.
Continuing letrozole therapy after 5 years of aromatase inhibitor therapy did not worsen quality-of-life measures in patients with HR-positive breast cancer.
Bladder cancer patients with tumors smaller than 1 cm could be classified as “very-low-risk,” with recurrences that could arise after the 5-year surveillance period.
The EGFR tyrosine kinase inhibitor osimertinib showed promising efficacy and manageable toxicity in patients with advanced NSCLC and CNS metastases.
Metastatic melanoma patients treated with pembrolizumab who achieve a complete response can maintain those responses, even after discontinuation of therapy.
BCR-ABL1 transcript levels at time points within the first year of therapy for CML can best predict the achievement of a deep molecular response.
An individual risk–based approach could identify more people eligible for lung cancer screening, and thus prevent more early deaths, compared with USPSTF criteria.
The combination of exosomal RNA and cell-free DNA improved the sensitivity of blood-based liquid biopsy for EGFR mutation detection in non–small-cell lung cancer compared with standard circulating tumor DNA.